A5055309480- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Cancer, Hypoxia, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Advanced Biosensing Techniques and Applications
- Cancer, Stress, Anesthesia, and Immune Response
- Lung Cancer Treatments and Mutations
- Glycosylation and Glycoproteins Research
Radboud University Nijmegen
2018-2024
Radboud University Medical Center
2018-2024
University Medical Center
2024
Radboud Institute for Molecular Life Sciences
2018-2022
PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired antigen-experienced anticancer T cells. However, the efficacy of current is potentially reduced 'on-target/off-tumor' binding to PD-L1 widely expressed on normal This lack tumor selectivity may induce a generalized activation all cells which explain frequent occurrence autoimmune-related adverse events during and after treatment. To address these issues, we...
Abstract Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of patients with cancer. PD-L1 expression tumors seems to be a prerequisite for treatment response. However, is heterogeneously expressed within tumor lesions may change upon disease progression treatment. Imaging could aid patient selection. Previously, we showed feasibility image PD-L1+ immunodeficient mice. also on immune cell subsets. Therefore,...
Abstract Background While immune checkpoint inhibitors such as anti-PD-L1 antibodies have revolutionized cancer treatment, only subgroups of patients show durable responses. Insight in the relation between clinical response, PD-L1 expression and intratumoral localization therapeutics could improve patient stratification. Therefore, we present modular synthesis multimodal antibody-based imaging tools for multiscale to study distribution therapeutics. Results To introduce modalities, a peptide...
Background Programmed death-ligand 1 (PD-L1) regulates immune homeostasis by promoting T-cell exhaustion. It is involved in chronic infections and tumor progression. Nuclear imaging using radiolabeled anti-PD-L1 antibodies can monitor PD-L1 tissue expression antibody distribution. However, physiological cause rapid clearance from blood at doses. Therefore, we hypothesized that inflammatory responses, which induce expression, affect Here, investigated the effects of three different infectious...
Abstract Many immunotherapies focus on (re)invigorating CD8 + T cell anti-cancer responses and different nuclear imaging techniques have been developed to measure distributions. In vivo labeling approaches using radiotracers primarily show distributions, while ex labeled cells can migration patterns, homing, tumor infiltration. Currently, a comprehensive head-to-head comparison of in ex-vivo with respect their normal tissue targeting properties correlation the presence is lacking, yet...
Abstract PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired anticancer T cells. However, their efficacy is potentially reduced ‘on-target/off-tumor' binding to PD-L1 widely expressed on normal This lack of tumor selectivity induces a generalized activation all antigen-experienced cells as evidenced frequent autoimmune-related adverse events during and after treatment. To address these issues, we constructed...
<p>Supplemental Figure 1</p>
<p>Supplemental Table 1</p>
<p>Supplemental Table 2</p>
<p>Supplemental Figure 3</p>
<p>Supplemental Figure 2</p>
<div>Abstract<p>Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of patients with cancer. PD-L1 expression tumors seems to be a prerequisite for treatment response. However, is heterogeneously expressed within tumor lesions may change upon disease progression treatment. Imaging could aid patient selection. Previously, we showed feasibility image PD-L1<sup>+</sup> immunodeficient mice....
<p>Supplemental Figure 3</p>
<p>Supplemental Table 1</p>
<p>Supplemental Table 2</p>
<p>Supplemental Figure 1</p>
<p>Supplemental Figure 2</p>
<div>Abstract<p>Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of patients with cancer. PD-L1 expression tumors seems to be a prerequisite for treatment response. However, is heterogeneously expressed within tumor lesions may change upon disease progression treatment. Imaging could aid patient selection. Previously, we showed feasibility image PD-L1<sup>+</sup> immunodeficient mice....
Background: Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of cancer patient. PD-L1 expression tumor seems to be a pre-requisite for treatment response. However, it is heterogeneously expressed within lesions may change upon disease progression treatment. Imaging could aid patient selection. Methods: Previously, we showed feasibility image positive tumors immunodeficient mice. also on immune cell subsets....